Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E W Ehrich

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The Journal of Rheumatology|November 11, 1999
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study GroupE W Ehrich, T J Schnitzer, H McIlwain, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain modelE W Ehrich, A Dallob, I De Lepeleire, et al.
Rheumatology (Oxford, England)|September 29, 1999
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2P Brooks, P Emery, J F Evans, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The Journal of Rheumatology|November 11, 1999
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study GroupE W Ehrich, T J Schnitzer, H McIlwain, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain modelE W Ehrich, A Dallob, I De Lepeleire, et al.
Rheumatology (Oxford, England)|September 29, 1999
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2P Brooks, P Emery, J F Evans, et al.
Pageof 2